Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
Valeritas Holdings Inc. (VLRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/02/2020 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Bankruptcy or Receivership, Compl...
Docs: "Amendment No. 2 to Asset Purchase Agreement"
03/20/2020 8-K Bankruptcy or Receivership, Other Events, Financial Statements and Exhibits
Docs: "Valeritas Receives Court Approval of Sale of Business to Zealand Pharma Will Result in the Retention of the Vast Majority of Valeritas Employees Enables Continued Production and Distribution of V-Go® Wearable Insulin Delivery Device"
03/18/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Amendment No.1 to Asset Purchase Agreement"
03/16/2020 8-K Quarterly results
02/28/2020 8-K Quarterly results
02/14/2020 8-K Quarterly results
02/10/2020 8-K Quarterly results
01/10/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/23/2019 8-K Quarterly results
12/20/2019 8-K Quarterly results
12/11/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "Corporate Presentation"
12/09/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "Valeritas Presents Positive h-Patch™ CBD Study Data as a Late-Breaking Presentation at the American Epilepsy Society 2019 Annual Meeting Presentation of data sets for both 40mg and 76mg of CBD Isolate Delivered via h-Patch™ System"
11/20/2019 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
11/15/2019 8-K Quarterly results
11/12/2019 8-K Quarterly results
10/21/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "GLP-1 Analogue Delivered Robustly via Subcutaneous Infusion with Valeritas Proprietary h-Patch™ Wearable Device in Preclinical Study - Company Plans to Explore Opportunities with Industry Partners Looking to Treat Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis with Incretin Mimetic -"
10/02/2019 8-K Quarterly results
09/13/2019 8-K Quarterly results
09/12/2019 8-K Quarterly results
09/06/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/15/2019 8-K Quarterly results
08/08/2019 8-K Quarterly results
Docs: "Valeritas Announces Second Quarter 2019 Financial Results Year-Over-Year Volume Growth in Target Accounts Grew 36%"
08/05/2019 8-K Quarterly results
07/30/2019 8-K Quarterly results
07/26/2019 8-K Other Events
07/09/2019 8-K Other Events
07/08/2019 8-K Other Events
Docs: "Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates Economic Advantages Compared to Multiple Daily Injection Therapy for Insulin Dependent Type 2 Diabetes Population"
06/27/2019 8-K Quarterly results
06/26/2019 8-K Quarterly results
06/10/2019 8-K Other Events
Docs: "Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates a Reduction in A1c Levels by 1.3 when Intensifying from a Basal Insulin Regimen to Basal-Bolus Delivery"
05/29/2019 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
Docs: "Valeritas to Participate in the American Diabetes Association’s 79th Scientific Sessions; Company Reiterates Second Quarter and Full-Year 2019 Revenue Guidance"
05/22/2019 8-K Other Events
Docs: "Valeritas’ V-Go® Demonstrates Positive Impact in Diabetes Quality Performance Measures in an Older Adult Population"
05/17/2019 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
Docs: "Valeritas Announces Reverse Stock Split"
05/10/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "Corporate Presentation"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy